Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

Risk stratification in acute myeloid leukemia (AML) remains principle in survival
prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) …

Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as “blast-
phase MPN”, is the most feared disease complication, with incidence estimates of 1–4% for …

Simple Summary The association of venetoclax (VEN) with hypomethylating agents (HMAs)
such as azacitidine (AZA) and decitabine (DECI) significantly improved the outcome of …

Background Venetoclax in combination with hypomethylating agents (HMA) is
revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large …

TP53‐altered myelodysplastic syndrome with excess blasts and TP53‐altered acute myeloid
leukemia should be considered under one unifying classification term for their study in …

Molecularly defined secondary acute myeloid leukemia is associated with a prior myeloid
neoplasm and confers a worse prognosis. We compared outcomes of molecularly defined …

Acute myeloid leukemia (AML) secondary to antecedent hematologic disorder or prior
therapeutics for cancer represent a diverse group of leukemias often associated with inferior …